MNG999
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.536
- MYC_TARGETS_V2+0.489
- MTORC1_SIGNALING+0.264
- UNFOLDED_PROTEIN_RESPONSE+0.264
- MYC_TARGETS_V1+0.260
- TNFA_SIGNALING_VIA_NFKB+0.247
- PANCREAS_BETA_CELLS+0.210
- PROTEIN_SECRETION+0.194
- HYPOXIA+0.155
- ADIPOGENESIS+0.154
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.476
- INTERFERON_GAMMA_RESPONSE-0.421
- ALLOGRAFT_REJECTION-0.349
- APICAL_SURFACE-0.302
- COMPLEMENT-0.287
- MYOGENESIS-0.267
- MITOTIC_SPINDLE-0.245
- G2M_CHECKPOINT-0.219
- INFLAMMATORY_RESPONSE-0.215
- E2F_TARGETS-0.199
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013593 | — | cohortA1 | 0.811 |
| 2 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.795 |
| 3 | TCGA-BB-A5HZ-01A-21R-A28V-07 | — | — | 0.789 |
| 4 | TCGA-CQ-6228-01A-11R-1915-07 | — | — | 0.781 |
| 5 | s0112303 | — | — | 0.768 |
| 6 | BS_TBWYAFSM | EPN | EPN Tumor | 0.768 |
| 7 | 52606_S129 | — | cohortA4 | 0.768 |
| 8 | 4ea93d27-97e3-40bd-8734-d026e48fbbe4 | — | — | 0.762 |
| 9 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.751 |
| 10 | SRR10899980 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.536 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.489 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.264 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.264 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.247 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.194 | Remibrutinib | — uncovered |
| HYPOXIA | 0.155 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.154 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.149 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.141 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.125 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.114 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.082 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.066 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.046 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.037 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.015 | Idelalisib | — uncovered |